Of clinical importance, we validated that inhibition of JUN drastically suppresses ovarian cancer cell growth and migration by employing the JUN/AP‐1 inhibitor T‐5224 that was used for treatment of inflammatory disorders (Figure 6G‐J),29 providing the first line of evidence of JUN as a potential druggable target in the treatment of ovarian cancer. This evidence concerns the gene FOS and ovarian carcinoma.